Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Tumor Treating Fields for Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT06124118
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT06117891
- Locations
- 🇺🇸
Mercy Medical Center - Medline Healthcare Services LLC, Baltimore, Maryland, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT06109272
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506, Rome, Roma, Italy
🇺🇸City of Hope /ID# 261468, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT06103864
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 20
- Registration Number
- NCT06094140
- Locations
- 🇦🇺
GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇦🇺Warringal Private Hospital, Melbourne, Victoria, Australia
Ascorbate with Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 36
- Registration Number
- NCT06083454
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷INS Bergonie, Bordeaux, France
Durvalumab and Oleclumab in Resectable PDAC
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT06060405
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Radioembolization with Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT06058663
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.